KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Long-Term Debt Repayments (2016 - 2017)

Regeneron Pharmaceuticals (REGN) has disclosed Long-Term Debt Repayments for 9 consecutive years, with -$25000.0 as the latest value for Q4 2017.

  • For Q4 2017, Long-Term Debt Repayments fell 110.0% year-over-year to -$25000.0; the TTM value through Sep 2018 reached -$25000.0, down 100.12%, while the annual FY2017 figure was $19.9 million, 54.26% up from the prior year.
  • Long-Term Debt Repayments hit -$25000.0 in Q4 2017 for Regeneron Pharmaceuticals, down from $7.1 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $221.4 million in Q4 2014 and bottomed at -$3.6 million in Q4 2013.
  • Average Long-Term Debt Repayments over 5 years is $17.4 million, with a median of $808500.0 recorded in 2013.
  • Year-over-year, Long-Term Debt Repayments crashed 706.15% in 2013 and then soared 6168.76% in 2014.
  • Regeneron Pharmaceuticals' Long-Term Debt Repayments stood at -$3.6 million in 2013, then skyrocketed by 6168.76% to $221.4 million in 2014, then tumbled by 99.56% to $968000.0 in 2015, then plummeted by 74.17% to $250000.0 in 2016, then tumbled by 110.0% to -$25000.0 in 2017.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at -$25000.0, $7.1 million, and $12.9 million for Q4 2017, Q2 2017, and Q1 2017 respectively.